Table 3.
Changes in TIL levels between primary and IBTR lesions for each TIL marker assessed.a
| CD3b | CD8b | CD4 | CD25 | FOXP3 | TIA1 | CD20 | CD68 | ||
|---|---|---|---|---|---|---|---|---|---|
| IBTR-all | Increase | 4 | 4 | 3 | 2 | 3 | 2 | 2 | 5 |
| No change | 6 | 6 | 11 | 9 | 7 | 8 | 12 | 5 | |
| Decrease | 5 | 4 | 0 | 3 | 4 | 4 | 1 | 3 | |
| IBTR-TR | Increase | 4 | 4 | 3 | 2 | 1 | 1 | 1 | 4 |
| No change | 2 | 2 | 4 | 3 | 5 | 4 | 5 | 1 | |
| Decrease | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 2 | |
| IBTR-NP | Increase | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| No change | 4 | 4 | 7 | 6 | 2 | 4 | 7 | 4 | |
| Decrease | 4 | 3 | 0 | 1 | 3 | 2 | 0 | 1 |
Notes:
a
Values indicate the number of IBTR cases with a ≥50% increase (‘increase’), less than a 50% change (‘no change’) or a ≥50% decrease (‘decrease’) in TIL levels relative to matched primary lesions.
b
Significant difference between TR and NP tumors (P < 0.05) using chi2 test for trend.